295 related articles for article (PubMed ID: 18637061)
1. Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
Kang JM; Kim N; Lee DH; Park YS; Kim JS; Chang IJ; Song IS; Jung HC
J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1287-91. PubMed ID: 18637061
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP2C19 and MDR1 genotype on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxycillin and clarithromycin.
Oh JH; Dong MS; Choi MG; Yoo HW; Lee SB; Park YI; Chung IS
J Gastroenterol Hepatol; 2009 Feb; 24(2):294-8. PubMed ID: 18823430
[TBL] [Abstract][Full Text] [Related]
3. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
Furuta T; Shirai N; Takashima M; Xiao F; Hanai H; Sugimura H; Ohashi K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 2001 Mar; 69(3):158-68. PubMed ID: 11240980
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy.
Prasertpetmanee S; Mahachai V; Vilaichone RK
Helicobacter; 2013 Aug; 18(4):270-3. PubMed ID: 23356886
[TBL] [Abstract][Full Text] [Related]
5. Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.
Ormeci A; Emrence Z; Baran B; Gokturk S; Soyer OM; Evirgen S; Akyuz F; Karaca C; Besisik F; Kaymakoglu S; Ustek D; Demir K
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):879-85. PubMed ID: 27010145
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.
Ozdil B; Akkiz H; Bayram S; Bekar A; Akgöllü E; Sandikçi M
Turk J Gastroenterol; 2010 Mar; 21(1):23-8. PubMed ID: 20533108
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Gawrońska-Szklarz B; Siuda A; Kurzawski M; Bielicki D; Marlicz W; Droździk M
Eur J Clin Pharmacol; 2010 Jul; 66(7):681-7. PubMed ID: 20376628
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis.
Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G
Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419
[TBL] [Abstract][Full Text] [Related]
9. Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.
Yang JC; Wang HL; Chern HD; Shun CT; Lin BR; Lin CJ; Wang TH
Pharmacotherapy; 2011 Mar; 31(3):227-38. PubMed ID: 21361732
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.
Sheu BS; Kao AW; Cheng HC; Hunag SF; Chen TW; Lu CC; Wu JJ
Aliment Pharmacol Ther; 2005 Feb; 21(3):283-8. PubMed ID: 15691303
[TBL] [Abstract][Full Text] [Related]
16. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
18. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.
Furuta T; Shirai N; Xiao F; Takashita M; Sugimoto M; Kajimura M; Ohashi K; Ishizaki T
Hepatogastroenterology; 2003; 50(54):2274-8. PubMed ID: 14696516
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Kim YS; Kim SJ; Yoon JH; Suk KT; Kim JB; Kim DJ; Kim DY; Min HJ; Park SH; Shin WG; Kim KH; Kim HY; Baik GH
Aliment Pharmacol Ther; 2011 Nov; 34(9):1098-105. PubMed ID: 21923713
[TBL] [Abstract][Full Text] [Related]
20. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy.
Kuo CH; Wang SS; Hsu WH; Kuo FC; Weng BC; Li CJ; Hsu PI; Chen A; Hung WC; Yang YC; Wang WM; Wu DC
Helicobacter; 2010 Aug; 15(4):265-72. PubMed ID: 20633187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
